Tumor-treating fields (TTF) represent a relatively novel treatment modality based on the delivery of low-intensity, intermediate-frequency (200kHz) alternating electrical fields that are thought to interfere with cellular proliferation by disrupting mitotic spindle formation during metaphase [1, 2]. Being a local treatment, glioblastoma emerged early on as a potentially paradigmatic disease to explore the potential clinical utility of TTF. For glioblastoma treatment, TTF were administered via transducer arrays attached to the scalp.
No takes yet. Share an insight, caveat, or question.
Michael Weller (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: